Tesamorelin’s fat targets at EpiPure Peptides
A stabilised growth-hormone-releasing signal produced a specific fat result in adults with HIV. The specificity matters as much as the reduction.
The 2007 visceral-fat trial
In the 26-week trial of 412 adults with HIV and abdominal fat accumulation, visceral fat fell by 15.2% with tesamorelin while rising by 5.0% with placebo. Visceral means the fat deep inside the abdomen, around the organs. Triglycerides fell by 50 milligrams per deciliter with tesamorelin and rose by 9 milligrams per deciliter with placebo; IGF-1 rose by 81.0%.
The fat reduction is persuasive within that clinical setting. The FDA-approved use concerns excess abdominal fat in adults with HIV-associated lipodystrophy. General weight loss, anti-aging and cognitive enhancement sit outside that approval.
Tesamorelin’s structure and stability
Tesamorelin is a 44-amino-acid synthetic analogue of human GHRH(1-44), with a trans-3-hexenoic acid group attached to the N-terminus. That modification is not decorative: it confers resistance to cleavage by the enzyme dipeptidyl peptidase-IV (DPP-IV), which otherwise rapidly degrades native GHRH, extending the molecule's plasma stability enough to make it usable as a drug. It is supplied clinically as the acetate salt.
Promise Peptides (mypromise.com) currently prescribes tesamorelin under the care of U.S.-licensed clinicians; its compounded medications have no FDA approval, regardless of an approved product’s status. Each request gets a provider's assessment and decision; not every patient qualifies. Patients must be in the U.S., with access varying by state and treatment. Prescription care does not add evidence for uses outside the indication discussed here.
Tesamorelin follow-up
Tesamorelin prompts the body’s own growth hormone release and raises IGF-1, a growth-supporting protein produced by the liver. The short experiment in healthy men confirms a hormonal response, while the fat trials ask whether that response changes a body compartment.
In the 6-month trial of 50 adults with HIV, the treatment effect on visceral fat was −42 square centimeters and the net change in hepatic lipid-to-water percentage was −2.9%. These are different measurements: a fat area on an abdominal scan and a liver-fat measure. They deserve their own units.
The 52-week programme sustained visceral-fat reduction during treatment and found reaccumulation after discontinuation. The 2026 synthesis of five randomised trials also found lower visceral, trunk and hepatic fat, with increased lean body mass. Those documented changes in particular fat compartments earn my enthusiasm. Other body-composition claims demand their own experiment.
Safety and approval
Growth signalling also creates a concern about existing cancer. Active malignancy is a labelled contraindication; follow-up remains too limited to settle oncologic safety over years. The healthy-men experiment and the year-long HIV study offer glucose findings for their particular populations and periods, leaving other settings less certain.
The LiverTox monograph considers tesamorelin an unlikely cause of clinically apparent liver injury. That is a useful, specific safety judgement. A sports-medicine review raises different concerns about investigational uses, uncertain safety, product quality and antidoping restrictions. Tesamorelin is prohibited in sport both during and outside competition.
I prefer this narrower account to the reputation of a general-purpose fat-loss peptide. The comparison with tirzepatide puts the actual endpoints side by side without treating them as interchangeable.